EntreMed Presents Preclinical Data for Novel PAR-2 Antagonist to Treat Cancer and Inflammatory Disea
Oral Presentation at the AACR Annual Meeting
April 19, 2005
ROCKVILLE, MD, April 19—EntreMed, Inc. (Nasdaq: ENMD) today announced the presentation of preclinical data for its Proteinase Activated Receptor (PAR-2) Inhibitor program. The data were highlighted yesterday in an oral presentation during the Inflammation, Microenvironment and Tumor Progression session at the American Association for Cancer Research (AACR) annual meeting in Anaheim, California.
PAR-2 is a cell surface receptor that is known to play a critical role in mediating acute and chronic inflammation. EntreMed has developed multiple peptides and small molecules that block PAR-2 activity, the first such compounds identified as PAR-2 antagonists. As part of a program to develop drug candidates for uses in oncology and other diseases, EntreMed has synthesized additional small molecule antagonists of PAR-2 that have demonstrated increased inhibitory activity in vitro compared to initial compounds.
Data from the Company’s preclinical studies indicate that its PAR-2 antagonists inhibit tumor growth and the formation of new blood vessels in animal models. PAR-2 antagonists also demonstrated inhibition of inflammation in preclinical rheumatoid arthritis and acute inflammation models. Antagonists of PAR-2 signaling demonstrate a potential relationship between the onset of inflammation and the regulation of tumor growth and angiogenesis.
Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief Medical Officer, commented on the presentation, “Identifying a PAR-2 mediated relationship between inflammation and cancer was a pivotal discovery. Through our preclinical studies with PAR-2, we have demonstrated that PAR-2 antagonists possess multiple actions including direct effects on inflammation, an important component of the disease process in cancer and rheumatoid arthritis.”
Dr. Sidor further commented, “PAR-2 is a novel target for inflammatory diseases and represents a key program in EntreMed’s pipeline. We are continuing to study the mechanisms-of-action for our compounds, identify additional small molecule PAR-2 antagonists, and determine the potential applications for PAR-2 antagonists in oncology and inflammatory diseases. We were pleased to have the opportunity to share these data with thought leaders in the oncology field.”
The PAR-2 program is part of an integrated EntreMed development effort, which is focused on a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases that attack disease cells directly and the blood vessels that nourish them. EntreMed’s product candidates target multiple disease pathways, including angiogenesis, inflammation, cell cycle regulation and apoptosis (programmed cell death). All intellectual property associated with the Company’s PAR-2 antagonists are owned exclusively by EntreMed.
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® NCD (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CASI Pharmaceuticals, Inc.